Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Jounce Therapeutics Inc (JNCE)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Jounce Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create a new watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
7.07 -0.30    -4.07%
11/06 - Closed. Currency in USD ( Disclaimer )
Pre Market
7.32
+0.25
+3.54%
4:43:12 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US4811161011 
CUSIP:  481116101
  • Volume: 495,434
  • Bid/Ask: 6.79 / 7.33
  • Day's Range: 6.78 - 7.15
Jounce Therapeutics 7.07 -0.30 -4.07%

JNCE Income Statement

 
Featured here, the Income Statement (earnings report) for Jounce Therapeutics Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
Collapse All
Period Ending: 2021
31/03
 2020
31/12
 2020
30/09
 2020
30/06
Total Revenue 1.54 62.34 - -
Revenue 1.54 62.34 - -
Other Revenue, Total - - - -
Cost of Revenue, Total - - - -
Gross Profit - - - -
Total Operating Expenses 28.12 26.92 25.1 28.25
Selling/General/Admin. Expenses, Total 7.62 6.9 7.1 7.23
Research & Development 20.51 20.02 18 21.02
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating - - - -
Unusual Expense (Income) - - - -
Other Operating Expenses, Total - - - -
Operating Income -26.58 35.42 -25.1 -28.25
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - - -
Other, Net 0.05 0.05 0.2 0.28
Net Income Before Taxes -26.53 35.47 -24.9 -27.96
Provision for Income Taxes - - - -
Net Income After Taxes -26.54 35.47 -24.9 -27.97
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items -26.54 35.47 -24.9 -27.97
Total Extraordinary Items - - - -
Net Income -26.54 35.47 -24.9 -27.97
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items -26.54 35.47 -24.9 -27.97
Dilution Adjustment - - - -
Diluted Net Income -26.54 35.47 -24.9 -27.97
Diluted Weighted Average Shares 45.96 39.46 34.16 34.05
Diluted EPS Excluding Extraordinary Items -0.58 0.9 -0.73 -0.82
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS -0.58 0.9 -0.73 -0.82
* In Millions of USD (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

JNCE Comments

Write your thoughts about Jounce Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Otto Gonzalez
Otto Gonzalez Sep 01, 2020 7:44PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I was ready to dump this stock and was waiting for the 7.45 range so I can break even since May timeline...I never expected the good news today.. this will explode with big pharma investors...I was pleasantly surprised today with this news. this originally had a target price of 9.50 and it should be a good investment for 2021..so hold on for the ride! ..
Reply
0 0
Report
Fred Seow
Fred Seow Sep 01, 2020 12:20PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Worth 0.8B
Reply
0 0
Report
Fred Seow
Fred Seow Sep 01, 2020 10:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gilead signs with Jnce and will pay $35m upfront in shares and later up to $685m royalties, great news for Jnce
Reply
0 0
Report
Jose Rodriguez
Jose Rodriguez Aug 10, 2020 5:44AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hello ! somebody have any new regarding JNCE, will it go up soon?
Reply
0 0
Report
Jeong Roh
Jeong Roh Jan 20, 2020 7:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
target: $15
Reply
1 0
Report
coach Shez
coach Shez Jun 04, 2018 3:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Short this ?
Reply
1 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email